Human Touch Behavioral Health Introduces Intravenous Ketamine Therapy for Mental Health Treatment
Human Touch Behavioral Health has announced the official launch of its new intravenous ketamine therapy service, a medical treatment now available to patients dealing with depression, anxiety, PTSD, and other treatment-resistant mental health conditions. The program is now open for consultation and intake at its Sacramento clinic.
This new offering marks a significant development in the organization's commitment to providing comprehensive and evidence-based mental health care. Administered under the supervision of licensed medical professionals in a controlled clinical setting, intravenous (IV) ketamine therapy has gained growing recognition within psychiatric medicine for its rapid-acting effects in patients who have not responded to traditional treatment methods.
'Our goal has always been to improve access to innovative and effective therapies,' said Dr. Archana Trivedi, Founder and CEO of Human Touch Behavioral Health. 'With the addition of IV ketamine therapy, we're expanding treatment options for individuals facing complex mental health challenges who deserve alternative pathways to relief.'
The ketamine treatment protocol at Human Touch Behavioral Health includes a full psychiatric evaluation, customized treatment planning, medical monitoring, and counselling. Sessions take place in a calm and supportive environment designed to promote safety and healing.
Human Touch Behavioral Health is a mental health provider offering a range of services, including individual and group therapy, psychiatric medication management, electro-convulsive therapy, transcranial magnetic stimulation, and now, ketamine therapy. The clinic is known for its multidisciplinary approach to patient care, with an emphasis on individualized treatment plans, trauma-informed practices, and a commitment to ethical, research-supported methods.
The new ketamine program is now accepting referrals and new patient consultations. Eligibility for IV ketamine therapy is determined through a comprehensive clinical assessment by the Human Touch Behavioral Health care team.
For more information on intravenous ketamine therapy or to schedule a consultation, visit https://humantouchbh.com or contact Human Touch Behavioral Health directly by calling us at: (916) 359-2950.
Media Inquiries
For interviews, media kits, or press opportunities, please contact:
Rachel Magallanes
Office ManagerHuman Touch Behavioral Health
info@humantouchbh.com | (916) 359-2950
About Human Touch Behavioral Health
Human Touch Behavioral Health is a forward-thinking mental health practice dedicated to empowering individuals through innovative, personalized, and compassionate care. Founded by Dr. Archana Trivedi, Human Touch Behavioral Health continues to lead the charge in redefining psychiatric treatment for the modern era.
Media Contact
Company Name: Human Touch Behavioral Health, CLL
Contact Person: Dr. Archana Trivedi
Email: Send Email
Phone: (916) 359-2950
Country: United States
Website: https://humantouchbh.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
an hour ago
- Globe and Mail
MRK's ADC Candidate Gets FDA Breakthrough Therapy Tag for Lung Cancer
Merck MRK announced that the FDA has granted the Breakthrough Therapy designation (BTD) to its B7-H3-directed DXd antibody-drug conjugate (ADC), ifinatamab deruxtecan (I-DXd), for treating adult patients with extensive-stage small cell lung cancer whose disease progressed on or after platinum-based chemotherapy. The FDA's Breakthrough Therapy designation is a process that speeds up the development and review of drugs for serious or life-threatening conditions. This designation is granted when early clinical evidence suggests that a drug may significantly improve over existing treatments on one or more important clinical measures. The FDA's latest decision was based on data from the phase II IDeate-Lung01 study with support from the phase I/II IDeate-PanTumor01 study. The IDeate-Lung01 study evaluated the safety and efficacy of I-DXdin in the given patient population. MRK Stock Performance Year to date, shares of Merck have plunged 15.3% compared with the industry 's decline of 2.8%. MRK & Daiichi's Deal for I-DXd & Other ADC Candidates Besides extensive-stage small cell lung cancer, I-DXd is being evaluated in separate phase III studies for treating esophageal cancer and prostate cancer. Developed by Daiichi Sankyo, this ADC drug candidate already enjoys an orphan drug designation for treating small-cell lung cancer in the United States, Europe and some other countries. Merck acquired global co-development and co-commercialization rights to I-DXd and two other ADCs, patritumab deruxtecan and raludotatug deruxtecan, from Daiichi Sankyo in October 2023 for a total potential consideration of up to $22 billion. However, Daiichi Sankyo has retained exclusive rights for the development of the candidates in Japan. In August last year, Merck expanded the collaboration to co-develop and co-commercialize MK-6070, an investigational T-cell engager targeting delta-like ligand 3 (DLL3), which it obtained from its recent acquisition of Harpoon Therapeutics. Patritumab deruxtecan is being developed in late-stage studies for breast cancer, while raludotatug deruxtecan is being developed in mid-stage studies for ovarian cancer as well as other cancer indications. Competition in the ADC Space ADCs are being considered a disruptive innovation in the pharmaceutical industry, as these will enable better treatment of cancer by harnessing the targeting power of antibodies to deliver cytotoxic molecule drugs to tumors. Daiichi Sankyo has several ADCs in clinical development across multiple types of cancer. It markets Enhertu, a HER2-directed ADC, in partnership with AstraZeneca AZN, which is presently approved across multiple indications, including HER2-mutated breast, lung and gastric cancers. In January 2025, the FDA approved AZN and Daiichi's second ADC drug, Datroway, for treating unresectable or metastatic HR-positive, HER2-negative breast cancer in adult patients who have received prior endocrine-based therapy and chemotherapy. The FDA approved Datroway for its second indication, non-small-cell lung cancer, in June. Pfizer PFE also forayed into the lucrative ADC space with the acquisition of Seagen for $43 billion in late 2023. Following this acquisition, PFE added three ADCs to its portfolio — Adcetris, Padcev, Tukysa and Tivdak — all approved across various types of solid tumors and hematologic malignancies. These products contributed meaningfully to Pfizer's revenues in 2024 and in the first half of 2025. MRK's Zacks Rank Merck currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. See our %%CTA_TEXT%% report – free today! 7 Best Stocks for the Next 30 Days Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report AstraZeneca PLC (AZN): Free Stock Analysis Report Pfizer Inc. (PFE): Free Stock Analysis Report Merck & Co., Inc. (MRK): Free Stock Analysis Report
Globe and Mail
2 hours ago
- Globe and Mail
Nutriband (NASDAQ: NTRB) to Present at Emerging Growth Conference on August 20
Nutriband (NASDAQ: NTRB) announced it will participate in the Emerging Growth Conference on August 20, 2025. Chairman Serguei Melnik will deliver a live, interactive presentation and may open the floor for real-time questions from shareholders and the investment community. To view the full article, visit About Nutriband Inc. We are primarily engaged in the development of a portfolio of transdermal pharmaceutical products. Our lead product under development is an abuse-deterrent fentanyl patch incorporating our AVERSA(TM) abuse-deterrent technology. AVERSA(TM) technology can be incorporated into any transdermal patch to prevent the abuse, misuse, diversion, and accidental exposure of drugs with abuse potential. About BioMedWire BioMedWire ('BMW') is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today's market, BMW brings its clients unparalleled recognition and brand awareness. BMW is where breaking news, insightful content and actionable information converge. To receive SMS alerts from BioMedWire, 'Biotech' to 888-902-4192 (U.S. Mobile Phones Only) For more information, please visit Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: BioMedWire Austin, Texas 512.354.7000 Office Editor@ BioMedWire is powered by IBN
CTV News
3 hours ago
- CTV News
Golfer says he ‘overdosed' on creatine during BMW Championship
American golfer Ben Griffin got the shakes at the BMW Championship – though it wasn't necessarily because of nerves, but rather due to swallowing a 'large rock' of creatine. (Nick Wass/AP via CNN Newsource) American golfer Ben Griffin got the shakes at the BMW Championship – though it wasn't necessarily because of nerves, but rather due to swallowing a 'large rock' of creatine. World No. 17 Griffin said that he 'started getting super shaky' and 'felt like I had tremors' on Sunday after accidentally swallowing a large amount of the supplement. Creatine 'contributes to rapid energy production and may enhance power or speed bursts requiring short periods of anaerobic activity,' according to Harvard Health, and usage of the supplement is common among gym enthusiasts as there is evidence it 'can hasten muscle recovery after strenuous exercise.' 'I've taken it on the golf course before. It's fine,' Griffin said, per the PGA Tour. 'I started taking it after my second shot, and I accidentally swallowed one of the big rocks in my water bottle. I've never overdosed on creatine before, but I think I did in the moment because I didn't really drink any water after that. I basically just inhaled a snowball,' the two-time PGA Tour winner explained. Griffin said that he usually takes 15mg of the supplement daily, but on this occasion, he estimates he accidentally ingested that amount at one time. 'I was physically shaking like I've never felt before,' Griffin said. 'And I don't normally miss a lot of short putts. It was really a weird situation.' The golfer said that his caddie intervened by making him drink water and calming him down. Griffin was six over par for the first three holes – carding a triple-bogey, double-bogey and bogey – and the golfer thought about withdrawing from the tournament, but after that, he said the physical effects started to wear off. He then made seven birdies and signed for a one-under 69, finishing tied for 12th in an impressive comeback. 'It was probably more just a little bit flustered. I was fine after the second shot on two. And then it was – I felt good so I went about my day and got it back to under par,' he said. The golfer said he will be limiting his intake of the supplement in future, calling the events of the day a 'pretty crazy story.' 'I don't think I'll be taking too much creatine in the future. I will take it, but not in the amount that I probably did on the golf course, which wasn't probably a healthy amount.'
